Puma Biotechnology
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
Home About Us Product Pipeline News Investors Contacts Careers

News

Recent Press Releases Archives

Archives

2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

2011 News Releases

December 9, 2011 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Read

November 23, 2011 - Puma Biotechnology Announces Completion of Private Placement Raises second tranche of capital bringing total offering proceeds to $60 Million
Read

October 5, 2011 - Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational PanHER Inhibitor; Closes $55 Million Private Placement and Completes Merger
Read




2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011


Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax